# Inogen Inc: financial statements, quarterly

INGN · Nasdaq · CIK 1294133 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ingn.md) · [Financials](/companies/ingn/financials.md) · [Filings](/companies/ingn/filings.md) · [Insiders](/companies/ingn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ingn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [68.0](/filings/0000950170-24-124115.md) | [59.4 d](/filings/0001193125-26-082630.md) | [63.1](/filings/0000950170-25-066966.md) | [74.4](/filings/0000950170-25-105835.md) | [74.9](/filings/0001193125-25-269484.md) | [66.3 d](/filings/0001193125-26-082630.md) | [68.5](/filings/0001294133-26-000016.md) | [79.2](/filings/0001294133-26-000034.md) | [79.1](/filings/0001193125-25-269484.md) | [68.6 d](/filings/0001193125-26-082630.md) | [72.4](/filings/0001294133-26-000016.md) | [83.5](/filings/0001294133-26-000034.md) |
| Cost of revenue | $m | [50.2](/filings/0000950170-24-124115.md) | [47.7 d](/filings/0001193125-26-082630.md) | [43.7](/filings/0000950170-25-066966.md) | [46.0](/filings/0000950170-25-105835.md) | [47.5](/filings/0001193125-25-269484.md) | [43.8 d](/filings/0001193125-26-082630.md) | [45.9](/filings/0001294133-26-000016.md) | [50.9](/filings/0001294133-26-000034.md) | [51.1](/filings/0001193125-25-269484.md) | [46.5 d](/filings/0001193125-26-082630.md) | [47.2](/filings/0001294133-26-000016.md) | [51.8](/filings/0001294133-26-000034.md) |
| Gross profit | $m | [33.8](/filings/0000950170-24-124115.md) | [28.2 d](/filings/0001193125-26-082630.md) | [34.4](/filings/0000950170-25-066966.md) | [42.7](/filings/0000950170-25-105835.md) | [41.3](/filings/0001193125-25-269484.md) | [36.3 d](/filings/0001193125-26-082630.md) | [36.4](/filings/0001294133-26-000016.md) | [41.3](/filings/0001294133-26-000034.md) | [41.3](/filings/0001193125-25-269484.md) | [35.2 d](/filings/0001193125-26-082630.md) | [37.9](/filings/0001294133-26-000016.md) | [43.3](/filings/0001294133-26-000034.md) |
| Research and development | $m | [4.5](/filings/0000950170-24-124115.md) | [6.7 d](/filings/0001193125-26-082630.md) | [6.6](/filings/0000950170-25-066966.md) | [5.6](/filings/0000950170-25-105835.md) | [3.5](/filings/0001193125-25-269484.md) | [5.9 d](/filings/0001193125-26-082630.md) | [4.0](/filings/0001294133-26-000016.md) | [5.2](/filings/0001294133-26-000034.md) | [4.8](/filings/0001193125-25-269484.md) | [5.3 d](/filings/0001193125-26-082630.md) | [5.1](/filings/0001294133-26-000016.md) | [5.9](/filings/0001294133-26-000034.md) |
| Operating income | $m | [(46.7)](/filings/0000950170-24-124115.md) | [(29.0) d](/filings/0001193125-26-082630.md) | [(16.3)](/filings/0000950170-25-066966.md) | [(7.1)](/filings/0000950170-25-105835.md) | [(7.8)](/filings/0001193125-25-269484.md) | [(11.4) d](/filings/0001193125-26-082630.md) | [(7.7)](/filings/0001294133-26-000016.md) | [(6.1)](/filings/0001294133-26-000034.md) | [(7.1)](/filings/0001193125-25-269484.md) | [(9.3) d](/filings/0001193125-26-082630.md) | [(9.3)](/filings/0001294133-26-000016.md) | [(5.1)](/filings/0001294133-26-000034.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.4](/filings/0000950170-24-124115.md) | [(0.5) d](/filings/0001193125-26-082630.md) | [(0.2)](/filings/0000950170-25-066966.md) | [(0.0)](/filings/0000950170-25-105835.md) | [(0.1)](/filings/0001193125-25-269484.md) | [(0.3) d](/filings/0001193125-26-082630.md) | [(0.1)](/filings/0001294133-26-000016.md) | [(0.2)](/filings/0001294133-26-000034.md) | [(0.1)](/filings/0001193125-25-269484.md) | [(0.2) d](/filings/0001193125-26-082630.md) | [(0.2)](/filings/0001294133-26-000016.md) | [(0.2)](/filings/0001294133-26-000034.md) |
| Net income | $m | [(45.7)](/filings/0000950170-24-124115.md) | [(26.6) d](/filings/0001193125-26-082630.md) | [(14.6)](/filings/0000950170-25-066966.md) | [(5.6)](/filings/0000950170-25-105835.md) | [(6.0)](/filings/0001193125-25-269484.md) | [(9.8) d](/filings/0001193125-26-082630.md) | [(6.2)](/filings/0001294133-26-000016.md) | [(4.2)](/filings/0001294133-26-000034.md) | [(5.3)](/filings/0001193125-25-269484.md) | [(7.1) d](/filings/0001193125-26-082630.md) | [(8.3)](/filings/0001294133-26-000016.md) | [(3.9)](/filings/0001294133-26-000034.md) |
| Diluted EPS | $ per share | [(1.97)](/filings/0000950170-24-124115.md) | not reported | [(0.62)](/filings/0000950170-25-066966.md) | [(0.24)](/filings/0000950170-25-105835.md) | [(0.25)](/filings/0001193125-25-269484.md) | not reported | [(0.25)](/filings/0001294133-26-000016.md) | [(0.15)](/filings/0001294133-26-000034.md) | [(0.20)](/filings/0001193125-25-269484.md) | not reported | [(0.30)](/filings/0001294133-26-000016.md) | [(0.14)](/filings/0001294133-26-000034.md) |
| Basic EPS | $ per share | [(1.97)](/filings/0000950170-24-124115.md) | not reported | [(0.62)](/filings/0000950170-25-066966.md) | [(0.24)](/filings/0000950170-25-105835.md) | [(0.25)](/filings/0001193125-25-269484.md) | not reported | [(0.25)](/filings/0001294133-26-000016.md) | [(0.15)](/filings/0001294133-26-000034.md) | [(0.20)](/filings/0001193125-25-269484.md) | not reported | [(0.30)](/filings/0001294133-26-000016.md) | [(0.14)](/filings/0001294133-26-000034.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [125](/filings/0000950170-23-061784.md) | [125](/filings/0001193125-26-082630.md) | [107](/filings/0000950170-24-055627.md) | [97.9](/filings/0000950170-25-105835.md) | [106](/filings/0001193125-25-269484.md) | [114](/filings/0001193125-26-082630.md) | [119](/filings/0001294133-26-000016.md) | [104](/filings/0001294133-26-000034.md) | [106](/filings/0001193125-25-269484.md) | [104](/filings/0001294133-26-000034.md) | [93.1](/filings/0001294133-26-000016.md) | [87.3](/filings/0001294133-26-000034.md) |
| Current assets | $m | [225](/filings/0000950170-23-061784.md) | [207](/filings/0000950170-25-029993.md) | [199](/filings/0000950170-24-055627.md) | [195](/filings/0000950170-24-092743.md) | [193](/filings/0000950170-24-124115.md) | [185](/filings/0001193125-26-082630.md) | [201](/filings/0000950170-25-066966.md) | [203](/filings/0000950170-25-105835.md) | [204](/filings/0001193125-25-269484.md) | [198](/filings/0001294133-26-000034.md) | [191](/filings/0001294133-26-000016.md) | [194](/filings/0001294133-26-000034.md) |
| Total assets | $m | [344](/filings/0000950170-23-061784.md) | [326](/filings/0000950170-25-029993.md) | [316](/filings/0000950170-24-055627.md) | [309](/filings/0000950170-24-092743.md) | [306](/filings/0000950170-24-124115.md) | [296](/filings/0001193125-26-082630.md) | [308](/filings/0000950170-25-066966.md) | [312](/filings/0000950170-25-105835.md) | [307](/filings/0001193125-25-269484.md) | [299](/filings/0001294133-26-000034.md) | [286](/filings/0001294133-26-000016.md) | [286](/filings/0001294133-26-000034.md) |
| Current liabilities | $m | [60.4](/filings/0000950170-23-061784.md) | [72.5](/filings/0000950170-25-029993.md) | [73.9](/filings/0000950170-24-055627.md) | [72.2](/filings/0000950170-24-092743.md) | [72.4](/filings/0000950170-24-124115.md) | [76.7](/filings/0001193125-26-082630.md) | [65.5](/filings/0000950170-25-066966.md) | [67.1](/filings/0000950170-25-105835.md) | [64.9](/filings/0001193125-25-269484.md) | [63.5](/filings/0001294133-26-000034.md) | [61.4](/filings/0001294133-26-000016.md) | [70.9](/filings/0001294133-26-000034.md) |
| Total liabilities | $m | [113](/filings/0000950170-23-061784.md) | [121](/filings/0000950170-25-029993.md) | [124](/filings/0000950170-24-055627.md) | [121](/filings/0000950170-24-092743.md) | [121](/filings/0000950170-24-124115.md) | [122](/filings/0001193125-26-082630.md) | [110](/filings/0000950170-25-066966.md) | [113](/filings/0000950170-25-105835.md) | [110](/filings/0001193125-25-269484.md) | [106](/filings/0001294133-26-000034.md) | [103](/filings/0001294133-26-000016.md) | [111](/filings/0001294133-26-000034.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [231](/filings/0000950170-24-124115.md) | [205](/filings/0001193125-26-082630.md) | [192](/filings/0000950170-25-105835.md) | [188](/filings/0001193125-25-269484.md) | [185](/filings/0001193125-25-269484.md) | [174](/filings/0001294133-26-000034.md) | [198](/filings/0001294133-26-000034.md) | [199](/filings/0001294133-26-000034.md) | [197](/filings/0001193125-25-269484.md) | [192](/filings/0001294133-26-000034.md) | [183](/filings/0001294133-26-000034.md) | [175](/filings/0001294133-26-000034.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [2.2 d](/filings/0000950170-24-124115.md) | [(3.1) d](/filings/0001193125-26-082630.md) | [(4.7)](/filings/0000950170-25-066966.md) | [6.7 d](/filings/0000950170-25-105835.md) | [7.0 d](/filings/0001193125-25-269484.md) | [(3.0) d](/filings/0001193125-26-082630.md) | [(16.8)](/filings/0001294133-26-000016.md) | [4.4 d](/filings/0001294133-26-000034.md) | [2.2 d](/filings/0001193125-25-269484.md) | [(0.9) d](/filings/0001193125-26-082630.md) | [(6.7)](/filings/0001294133-26-000016.md) | [2.9 d](/filings/0001294133-26-000034.md) |
| Capital expenditure | $m | [0.7 d](/filings/0000950170-24-124115.md) | [1.4 d](/filings/0001193125-26-082630.md) | [1.3](/filings/0000950170-25-066966.md) | [0.1 d](/filings/0000950170-25-105835.md) | [1.7 d](/filings/0001193125-25-269484.md) | [0.3 d](/filings/0001193125-26-082630.md) | [0.3](/filings/0001294133-26-000016.md) | [0.7 d](/filings/0001294133-26-000034.md) | [0.6 d](/filings/0001193125-25-269484.md) | [1.0 d](/filings/0001193125-26-082630.md) | [0.2](/filings/0001294133-26-000016.md) | [0.7 d](/filings/0001294133-26-000034.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [1.9](/filings/0001294133-26-000016.md) | [5.6 d](/filings/0001294133-26-000034.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [22.9](/filings/0000950170-23-061784.md) | [23.0](/filings/0000950170-24-055627.md) | [23.1](/filings/0000950170-24-092743.md) | [23.2](/filings/0000950170-24-124115.md) | [23.4](/filings/0000950170-25-066966.md) | [23.6](/filings/0000950170-25-105835.md) | [23.8](/filings/0001193125-25-269484.md) | [25.2](/filings/0001294133-26-000016.md) | [27.0](/filings/0001294133-26-000034.md) | [27.1](/filings/0001193125-25-269484.md) | [27.3](/filings/0001294133-26-000016.md) | [27.0](/filings/0001294133-26-000034.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 26,538,337 at 2026-08-01, from the cover of the [10-Q filed 2026-08-07](/filings/0001294133-26-000034.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.